MedTrace Logo

The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

NCT01423188 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2012-09-20

No results posted yet for this study

Summary

This study is designed to provide an assessment of the change in baseline lipid parameters with RVX000222 after 12 weeks and 24 weeks of treatment when given in addition to optimized statin background therapy in subjects with low baseline HDL-C.

Conditions

Interventions

DRUG

RVX000222

capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks

DRUG

Placebo RVX000222

capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Resverlogix Corp

    lead INDUSTRY

Principal Investigators

  • Steve Nicholls, MBBS, PhD · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-06-30
Completion
2012-08-31

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01423188 on ClinicalTrials.gov